Hello from sunny SF

greigite

Senior Member

Join Date: Mar 2009

Posts: 145
- Share
- Tweet
#1

Hello from sunny SF

03-11-2009, 11:58 AM

Hello all
I am a postdoc in the SF Bay and very pleased to join this fantastic forum. I am new to NGS but eager to learn, particularly about 454 and Illumina. I will be working primarily with two kinds of data: shotgun sequencing of mixed microbial communities with 454 and isolate sequencing with Illumina G2. I am particularly interested in methods to discover and validate SNPs in this data, as well as de novo and reference based aligners.
Tags: None

Previous template Next

Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems

by mylaser

Kheloyaar: The Complete Guide to Kheloyaar Loginand Kheloyaar ID
The online gaming industry has transformed the way people enjoy digital entertainment. As technology continues to improve, players are looking for platforms that offer convenience, security, and a seamless user experience. Kheloyaarhas gained attention among users who value an easy-to-use platform, quick account access, and a simple registration process.
Whether you're exploring Kheloyaar for the first time or want to understand...
- Channel: Articles
Yesterday, 09:27 PM
Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems

by SEQadmin2

Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...
- Channel: Articles
Yesterday, 11:10 AM
Cancer Drug Resistance: The Lingering Barrier to Rising Survival

by SEQadmin2

Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
- Channel: Articles
07-08-2026, 05:17 AM

Topics	Statistics	Last Post
New Analysis Splits Leukemia Into 16 Epigenomic Subgroups by SEQadmin2 Started by SEQadmin2, Yesterday, 10:04 AM	0 responses 8 views 0 reactions	Last Post by SEQadmin2 Yesterday, 10:04 AM
Genome-Wide CRISPR Screen Uncovers Unlikely Psoriasis Target by SEQadmin2 Started by SEQadmin2, 07-08-2026, 10:08 AM	0 responses 7 views 0 reactions	Last Post by SEQadmin2 07-08-2026, 10:08 AM
Engineered Protein Motor Takes Its First Steps Along DNA Track by SEQadmin2 Started by SEQadmin2, 07-07-2026, 11:05 AM	0 responses 10 views 0 reactions	Last Post by SEQadmin2 07-07-2026, 11:05 AM
High-Resolution Sequencing Exposes Hidden Toxoplasma Diversity by SEQadmin2 Started by SEQadmin2, 07-02-2026, 11:08 AM	0 responses 31 views 0 reactions	Last Post by SEQadmin2 07-02-2026, 11:08 AM

Unconfigured Ad

Latest Articles

ad_right_rmr

News